Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis
Launched by NORDIC PHARMA SAS · Oct 14, 2021
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Major patient (age ≥ 18 years)
- • Patient with RA according to American College of Rheumatology (ACR) / European Congress of Rheumatology (EULAR) 2010 or ACR 1987 or patient with PsA according to ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria
- • Patient undergoing treatment with methotrexate (MTX) (oral or injectable) initiated for at least 3 months.
- • Naïve patient of biotherapy or tsDMARD and requiring the introduction of a first bDMARD or tsDMARD due to the activity of the disease.
- • Patient informed and accepting the computer processing of his/her medical data and informed of his/her rights of access and rectification.
- Exclusion Criteria:
- • Patient participating in an interventional study in rheumatology
- • Patient with axial spondyloarthritis (for patients with PsA)
About Nordic Pharma Sas
Nordic Pharma SAS is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic solutions for a range of medical conditions. With a strong focus on improving patient outcomes, Nordic Pharma leverages cutting-edge research and clinical expertise to advance its portfolio of products, particularly in the fields of oncology, neurology, and rare diseases. Committed to high standards of quality and regulatory compliance, the company collaborates with healthcare professionals and stakeholders worldwide to address unmet medical needs and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Hélène HERMAN-DEMARS, MD
Study Director
Nordic Pharma
René Marc FLIPO, Prof
Principal Investigator
CHRU Lille
Cécile GAUJOUX-VIALA, Dr
Principal Investigator
CHU Nîmes
Emmanuelle DERNIS, Dr
Principal Investigator
CH Le Mans
Éric SENBEL, Dr
Principal Investigator
Marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials